Transcripta Bio Raises $24 Million to Advance AI-Powered Drug Discovery Platform for Neurological and Neuromuscular Diseases
核心洞察
Transcripta Bio (搜索) has raised $24 million since its Series A to advance IND-enabling studies across its four-program pipeline targeting neurological and neuromuscular diseases.
Mayo Clinic and Omnimed (搜索) join existing investors JAZZ Venture Partners (搜索), BlueYard Capital (搜索), and life sciences family offices as the company prepares for human clinical trials.
The company's closed-loop discovery engine uses transcriptomic signature matching with a machine learning system trained on over one billion gene responses to de-risk drug development.
Transcripta Bio (搜索), an AI-powered drug discovery company based in Palo Alto, California, announced today it has raised $24 million since its Series A financing round to advance IND-enabling studies across its portfolio and support clinical preparation for its Autism Spectrum Disorder (搜索) (ASD) and Facioscapulohumeral Muscular Dystrophy (搜索) (FSHD) programs. The funding round brings new investors Mayo Clinic and Omnimed (搜索) alongside existing backers JAZZ Venture Partners (搜索), BlueYard Capital (搜索), and a group of life sciences family offices.
The company's pipeline spans four programs across Myotonic Dystrophy (搜索), FSHD, ASD, and Huntington's Disease (搜索) (HD), representing a concentrated effort to address neurological and neuromuscular conditions with significant unmet medical need.
A Closed-Loop Discovery Engine Grounded in Patient Biology
Transcripta Bio (搜索)'s platform is built around transcriptomic signature matching, an approach designed to identify drugs whose molecular signatures are the inverse of patient-derived disease signatures. The discovery engine integrates three core components: a Disease Signature Atlas constructed from actual patient single-cell RNA sequencing data, a Drug-Gene Atlas that maps the full transcriptomic response of both FDA-approved and novel compounds, and Conductor AI, a machine learning system trained on more than one billion gene responses.
Unlike conventional AI-driven drug discovery approaches that begin at hit identification, Conductor AI starts at the lead optimization stage. The company states that this integrated system is designed to systematically assess compounds with the goal of de-risking drug development by addressing the root causes of clinical failure before candidates ever reach the clinic.
"Transcripta was founded to address the failure points that keep drugs from reaching the clinic. Our platform has already demonstrated results and this capital accelerates that work for diseases that have waited long enough for real treatments," said Chris Moxham, founder and CEO of Transcripta Bio (搜索). "Transcripta Bio is positioned to demonstrate what AI-native drug discovery can deliver for patients with neurological and neuromuscular diseases."
Investor Confidence in AI-Native Drug Discovery
Greg Wood, Managing Director at Omnimed (搜索), emphasized the platform's grounding in patient-derived data: "Transcripta Bio (搜索) has developed a discovery platform grounded in patient biology and applied it across four programs with significant unmet need. We look forward to seeing what they can accomplish moving forward."
Mayo Clinic, which holds a financial interest in the technology referenced in the announcement, will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.
Pipeline Progress and Clinical Milestones
The new capital will be directed toward advancing IND-enabling studies across the company's entire portfolio, with particular focus on clinical preparation in the ASD and FSHD programs. The four-program pipeline targets diseases that currently lack adequate therapeutic options, positioning Transcripta Bio (搜索) to potentially address substantial gaps in the neurological and neuromuscular disease treatment landscape as it moves toward human clinical trials.